Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) EPS (Weighted Average and Diluted): 2021-2024

Historic EPS (Weighted Average and Diluted) for Heron Therapeutics (HRTX) over the last 4 years, with Dec 2024 value amounting to -$0.09.

  • Heron Therapeutics' EPS (Weighted Average and Diluted) fell 233.33% to -$0.10 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.09, marking a year-over-year increase of 43.75%. This contributed to the annual value of -$0.09 for FY2024, which is 88.75% up from last year.
  • As of FY2024, Heron Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.09, which was up 88.75% from -$0.80 recorded in FY2023.
  • Over the past 5 years, Heron Therapeutics' EPS (Weighted Average and Diluted) peaked at -$0.09 during FY2024, and registered a low of -$2.24 during FY2021.
  • Its 3-year average for EPS (Weighted Average and Diluted) is -$0.85, with a median of -$0.80 in 2023.
  • Data for Heron Therapeutics' EPS (Weighted Average and Diluted) shows a peak YoY spiked of 88.75% (in 2024) over the last 5 years.
  • Heron Therapeutics' EPS (Weighted Average and Diluted) (Yearly) stood at -$2.24 in 2021, then rose by 25.45% to -$1.67 in 2022, then skyrocketed by 52.10% to -$0.80 in 2023, then spiked by 88.75% to -$0.09 in 2024.